Brief Psychotic Disorder
10
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
Accelerated rTMS for Psychomotor Slowing
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
An Integrated Program for the Treatment of First Episode of Psychosis
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Effectiveness of the Individualized Metacognitive Training (EMC+) in People With Psychosis of Brief Evolution
Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia